Murine Typhus from Vietnam, Imported into Japan by Azuma, Momoyo et al.
tially infected water. Furthermore,
hypereosinophilia is an early warning
sign, as seroconversion and egg
excretion may be slower to evolve.
Both elements provide sufficient cir-
cumstantial evidence to strongly sus-
pect the diagnosis (2). In this case, the
full-blown Katayama syndrome con-
tributed to the evidence.
Praziquantel only kills adult
worms and does not inactivate schis-
tosomules, nor the miracidium inside
the eggs, which will continue to elicit
a damaging immunologic response
for some time. Early antischistosomal
treatment might, in fact, worsen
symptoms (7). Because schistoso-
mules may require up to 8 weeks to
mature, early postexposure treatment
with praziquantel cannot be used to
forestall disease after primary infec-
tion. Furthermore, Katayama syn-
drome may occur as early as 3 weeks
after exposure. On the other hand,
withholding praziquantel until larvae
have matured (8 weeks after expo-
sure) would not prevent Katayama
syndrome in many cases (7). Acute
symptoms, including early neu-
roschistosomiasis, may therefore still
develop during this 5-week window
after exposure, despite early prazi-
quantel administration.
Artemether has shown promising
activity against schistosomules (8).
Repeated administration throughout
the transmission season has prevented
Katayama syndrome in S. japonicum
infection (9). Its use, singly or in com-
bination with praziquantel, should be
investigated as true postexposure pro-
phylaxis for primary schistosomal
infection in nonimmune travelers
(10).
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To the Editor: In Vietnam, many
febrile diseases such as malaria,
dengue fever, Japanese encephalitis,
scrub typhus, and more recently,
severe acute respiratory syndrome
(SARS) and avian influenza have
been reported. Murine typhus cases
were also reported during and before
the 1960s but not thereafter (1–5).
On May 3, 2003, a 54-year-old
male resident of Tokushima, Japan,
had onset of fever in the suburban
town of Cu Chi, ≈60 km northwest of
Ho Chi Minh City, Vietnam.
Exanthema appeared on his trunk and
limbs on May 7. He returned to Japan
on May 9 and was admitted to
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Tokushima University Hospital on
May 10. His body temperature was
39.0°C, and serum, C-reactive protein
level was high (17.06 mg/dL) on
admission (day 8 of illness).
Unfortunately, the blood sample taken
on that day was discarded. We then
collected blood on days 10, 11, 12, 14,
17, and 24 of illness for diagnosis.
Minocycline was administered on day
8 and resulted in a gradual decrease in
fever and rash. Weil-Felix tests on day
12 showed the serum to be positive for
Proteus vulgaris OX19 (titer 160);
tests for P. vulgaris OX2 and OXK
were negative (titer of 10 for both).
We examined blood samples for pos-
sible diseases such as malaria, dengue
fever, SARS, and rickettsioses.
Giemsa-stained peripheral blood sam-
ples obtained on day 11 showed no
malarial parasites. Results of
immunoglobulin M (IgM)-capture
ELISA of serum on days 10, 11, and
17 of illness were negative for dengue
antibodies. Reverse transcription
(RT)–PCR of the serum on day 11 was
also negative. RT-PCRs of a pharyn-
geal swab and urine collected on day
11 were both negative for the SARS
coronavirus. These specimens were
also injected into Vero cells, and no
cytopathic effects were generated. RT-
PCR of these cultures was also nega-
tive for SARS coronavirus. Moreover,
SARS antibodies were not found in
serum samples on days 11 and 14 of
illness. Serum was also tested for
Orientia tsutsugamushi and  Coxiella
burnttii  on day 12 to exclude scrub
typhus and Q fever as diagnoses.
Indirect immunofluorescence tests
for etiologic agents of spotted fever,
murine typhus, and epidemic typhus
were then performed with serum sam-
ples collected on days 10, 14, and 24.
We used Rickettsia typhi and  R.
prowazekii as typhus group (TG) rick-
ettsial antigens and R. japonica and R.
conorii as spotted fever group (SFG)
rickettsiae. IgM antibody was detected
for these antigens, indicating that the
disease was a primary infection of
rickettsiae (Table). When TG and SFG
rickettsioses were compared, TG rick-
ettsiae represented markedly higher
elevated titers than SFG rickettsiae,
which excluded a diagnosis of SFG
rickettsiosis. PCR for the TG rick-
ettsial genome in the convalescent-
phase serum on day 10 was negative.
To demonstrate more detailed anti-
genic reactivity, Western immuno-
blotting was performed with serum on
day 14 (6). The serum reacted similar-
ly to the ladderlike lipopolysaccharide
(LPS) of R. typhi and R. prowazekii.
As expected from the group-specific
nature of rickettsial LPS, no reaction
was demonstrated to LPS of SFG
rickettsiae,  R. japonica and  R.
conorii, although weak reactivity,
mainly to the major outer member
protein of SFG rickettiae, rOmpB,
and molecules of smaller sizes was
shown (6,7). As described previously,
rOmpB has cross-reactive antigenici-
ty between TG and SFG rickettsiae
(6). Compared with the trace reaction
to rOmpB of SFG rickettsiae, an
extremely high level of reaction was
demonstrated to rOmpB of TG rick-
ettsiae. These results confirmed the
disease to be a TG rickettsiosis.
To elucidate whether the disease
was murine typhus or epidemic
typhus, we conducted cross-absorp-
tion tests as described previously
(8,9). Serum absorbed by R. typhi
showed complete absorption, demon-
strating no reaction to R. typhi or R.
prowazekii (Table). However, the
serum absorbed by R. prowazekii
resulted in incomplete absorption,
demonstrating no reactivity to R.
prowazekii but some reactivity to R.
typhi, which was left unabsorbed.
Western immunoblotting with the
serum absorbed by R. prowazekii
showed reactivity only to the rOmpB
of  R. typhi but not to that of R.
prowazekii. These results confirmed
the diagnosis of murine typhus.
This is the first serodiagnosis of
murine typhus in Vietnam since the
1960s (1–5). Since rats inhabit the
area where the patient acquired the ill-
ness, murine typhus seems to have
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occurred sporadically or endemically
but to have been undiagnosed since
the 1960s, maybe because it was
thought to have been eradicated and
thus widely forgotten. This case was
the first imported into Japan since the
1940s, when many Japanese soldiers
and residents who returned from
abroad had the disease.
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To the Editor: We conduct com-
municable disease risk assessments
after humanitarian emergencies,
including natural disasters, and would
like to clarify the findings of Floret et
al. (1) regarding the risk for epidemics
in certain disaster settings. Natural
disasters that do not result in popula-
tion displacement, regardless of type
of disaster, are rarely associated with
increased risk for epidemics.
However, large-scale population dis-
placement, with consequent over-
crowding in temporary settlements
and disruption of water supply and
sanitation, are indeed associated with
increased risks for communicable dis-
ease transmission. This distinction is
well documented (2–4). Increased
communicable disease incidence after
flooding and cyclones has been par-
ticularly well described (5,6). In addi-
tion, after a disaster of any type, epi-
demics may go undetected because of
poor surveillance or because baseline
surveillance data for diseases (such as
dengue fever or malaria) are unavail-
able.
Although we agree with the
authors that media reports are often
exaggerated and that the risk for epi-
demics after certain types of natural
disasters (e.g., volcanic eruption) is
low, we believe the findings are some-
what misleading. Postdisaster com-
municable disease incidence is related
more closely to the characteristics of
the displaced population (size, health
status, living conditions) than to the
precipitating event.
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